Successful Treatment of Myocardial Infarction in an Infant With Kawasaki Disease

Semin Cardiothorac Vasc Anesth. 2015 Sep;19(3):255-9. doi: 10.1177/1089253215573328. Epub 2015 Feb 19.

Abstract

Although early treatment with intravenous immunoglobulin reduces the risk of coronary artery aneurysms, in refractory cases of Kawasaki disease, myocardial infarction can result from thrombosis of coronary artery aneurysms. Early recognition of myocardial infarction from Kawasaki disease myocarditis can reduce morbidity and mortality. This report describes successful treatment of myocardial infarction from coronary thrombosis in an infant with Kawasaki disease using intravenous tissue plasminogen activator and abciximab.

Keywords: Kawasaki disease; abciximab; coronary artery aneurysms; coronary artery thrombosis; myocardial infarction; thrombolytics.

Publication types

  • Case Reports

MeSH terms

  • Abciximab
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use
  • Coronary Thrombosis / complications*
  • Coronary Thrombosis / drug therapy
  • Coronary Thrombosis / etiology
  • Fibrinolytic Agents / administration & dosage
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Immunoglobulin Fab Fragments / administration & dosage
  • Immunoglobulin Fab Fragments / therapeutic use
  • Infant
  • Male
  • Mucocutaneous Lymph Node Syndrome / complications*
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / etiology
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Aggregation Inhibitors / therapeutic use
  • Tissue Plasminogen Activator / administration & dosage
  • Tissue Plasminogen Activator / therapeutic use
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Fibrinolytic Agents
  • Immunoglobulin Fab Fragments
  • Platelet Aggregation Inhibitors
  • Tissue Plasminogen Activator
  • Abciximab